Sospension of androgen hormonal deprivation in patients with high levels of CgA - CgA
- Conditions
- Cancer histologic diagnosis of prostatic carcinoma in hormonal escapeMedDRA version: 9.1Level: HLTClassification code 10018187Term: Genitourinary neoplasms malignancy and gender unspecified
- Registration Number
- EUCTR2009-011257-40-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA S. LUIGI GONZAGA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
- Cancer histologic diagnosis of prostatic carcinoma
- hormanonal escape
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- lack chronic opf renal efficiency
- other diagnosis of cancer pathologies
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link high CgA levels to androgen deprivation resistance in prostatic carcinoma hormonal escape?
How does suspending androgen deprivation therapy compare to continuous ADT in CgA-high prostate cancer hormonal escape?
Which biomarkers predict response to androgen deprivation suspension in CgA-elevated prostate cancer patients?
What adverse events are associated with resuming androgen levels post-ADT suspension in CgA-high prostate cancer trials?
Are there combination therapies with AR inhibitors or immunotherapies that enhance outcomes when androgen deprivation is suspended in CgA-high prostate cancer?